Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. Their drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Nurix is focused on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.

Hans van Houte
Pierre Beaurang
Chief Business Officer
Gwenn M. Hansen
Chief Scientific Officer
Stefani A. Wolff
COO & EVP, Product Development
Michael T. Lotze
Chief Cellular Therapy Officer
Christine Ring
General Counsel & Secretary
Jason Kantor
SVP, Finance & Investment Strategy
Robert J. Brown
SVP of Clinical Development
Cristiana Guiducci
SVP, Immunology & Oncology Research
Daisy Chhokar
VP, Human Resources

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.